All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Biologics to seek approval for the candidate in China.

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

The FDA approval of Roche/Genentech's breast cancer drug T-DM1 (brand name Kadcyla) last week has caused a mixed reaction from healthcare analysts. The FDA approval of Roche/Genentech’s breast cancer ...

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount its ...

The FDA approval of Roche/Genentech’s breast cancer treatment Kadcyla last week comes amid new research showing disturbing prevalence rates of the disease among women. But the drug’s price leaves some ...

On the news, Kadcyla in this setting is now approved in 27 countries worldwide. The European Commission has approved Roche’s Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive ...

Breast cancer treatment Kadcyla, will remain available to patients after a last-minute deal on its price between NHS England and pharma company Roche. The drug was one of dozens marked for de-listing ...